Thursday, March 5, 2009
Carigent Therapeutics

Followed by networking, refreshments & wine bar

Carigent is a privately held biotechnology firm dedicated to the development of next-generation therapeutic agents using a versatile and robust proprietary platform.

The company has developed a novel technology for attaching high densities of application-specific molecules to the surfaces of biodegradable, polymeric particles ranging in size from tens of nanometers to hundreds of microns. The versatility of the platform enables the display of sophisticated combinations of ligands, adding new functionalities to biodegradable polymeric particles.

The company's technology allows, for example:

• delivery of multiple therapeutic modalities such as RNAi, peptides, small molecules, and therapeutic vaccines
  
• flexibility in targeting the drug delivery system for a variety of disease states and delivery routes
  
• enhancement of in vivo circulation times

The company believes that the benefits of sustained-release, targeted delivery, and long-lasting high density surface functionalities position the Carigent technology as a premier drug delivery vehicle in a range of clinical therapeutic applications for cancer, cardiovascular, autoimmune, and alloimmune disease.

Carigent's general strategy is to continue to develop its technical platforms, both internally and in collaboration with larger partners.

The Yale BioHaven Entrepreneurship Series features presentations designed to showcase regionally developed life science technologies that have progressed along the path to commercialization.  Speakers at the BioHaven events represent both the scientific and business side of the enterprises.

The programs focus on key success factors of each company, scientific or technological advantage, business model, and lessons learned in starting and developing the business. The series also provides social networking opportunities for scientists/researchers in the Yale community.

Speakers